2019
Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing
Wu Y, Warner J, Wang L, Jiang M, Xu J, Chen Q, Nian H, Dai Q, Du X, Yang P, Denny J, Liu H, Xu H. Discovery of Noncancer Drug Effects on Survival in Electronic Health Records of Patients With Cancer: A New Paradigm for Drug Repurposing. JCO Clinical Cancer Informatics 2019, 3: cci.19.00001. PMID: 31141421, PMCID: PMC6693869, DOI: 10.1200/cci.19.00001.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterCancer survivalMayo ClinicDrug repurposingNoncancer drugsElectronic health record dataCancer registry dataEHR dataClinical trial evaluationOverall cancer survivalUniversity Medical CenterHealth record dataElectronic health recordsTreatment of cancerClinical trialsDrug classesRegistry dataMedical CenterDrug effectsSignificant associationLongitudinal EHRNew indicationsPatientsCancerHealth records
2012
Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records
Liu M, Hinz E, Matheny M, Denny J, Schildcrout J, Miller R, Xu H. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. Journal Of The American Medical Informatics Association 2012, 20: 420-426. PMID: 23161894, PMCID: PMC3628053, DOI: 10.1136/amiajnl-2012-001119.Peer-Reviewed Original ResearchConceptsAdverse drug reactionsElectronic medical recordsProportional reporting ratioVanderbilt University Medical CenterSpontaneous reporting systemDrug-event pairsDrug reactionsMedical recordsMedication ordersAbnormal laboratory resultsDrug-exposed groupNew adverse drug reactionsUniversity Medical CenterSpecific drug administrationReference standardLaboratory resultsUnexposed groupGamma Poisson ShrinkerMedical CenterPatient harmDrug AdministrationPharmacovigilance measuresBayesian confidence propagation neural networkEarly detectionReporting ratioOptimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping
Schildcrout J, Denny J, Bowton E, Gregg W, Pulley J, Basford M, Cowan J, Xu H, Ramirez A, Crawford D, Ritchie M, Peterson J, Masys D, Wilke R, Roden D. Optimizing Drug Outcomes Through Pharmacogenetics: A Case for Preemptive Genotyping. Clinical Pharmacology & Therapeutics 2012, 92: 235-242. PMID: 22739144, PMCID: PMC3785311, DOI: 10.1038/clpt.2012.66.Peer-Reviewed Original ResearchConceptsVanderbilt University Medical CenterAdverse eventsPreemptive genotypingPotential adverse eventsUniversity Medical CenterHome patientsPharmacogenetic associationsMedical CenterVariant allelesMedicationsDrug outcomesPatient safetyDrug decision makingRelevant genetic variantsRoutine integrationTarget drugsGenetic variantsOutcomesFrequency of opportunitiesGenotypingSafetyPrescribingPatientsCohortPharmacogeneticsUnderstanding patient‐provider communication entered via a patient portal system
Sun S, Zhou X, Denny J, Rosenbloom T, Xu H. Understanding patient‐provider communication entered via a patient portal system. Proceedings Of The American Society For Information Science And Technology 2012, 49: 1-4. DOI: 10.1002/meet.14504901175.Peer-Reviewed Original ResearchUnderstanding patient‐provider communication entered via a patient portal system
Sun S, Zhou X, Denny J, Rosenbloom T, Xu H. Understanding patient‐provider communication entered via a patient portal system. Proceedings Of The American Society For Information Science And Technology 2012, 49: 1-4. DOI: 10.1002/meet.14504901387.Peer-Reviewed Original Research